Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response ...

The PR.21 study found no significant difference in rPFS between 177Lu-PSMA-617 and docetaxel in mCRPC patients. 177Lu-PSMA-617 showed a higher PSA response rate compared to docetaxel, with 36% vs 16% ...

Panelists discuss how IsoPSA’s long-term predictive performance supports safer follow-up strategies and greater confidence in risk-based management. Panelists discuss how IsoPSA’s predictive ...

Pasritamig targets KLK2 and has FDA fast track designation for mCRPC, enabling accelerated development and review processes. Phase 1 study showed pasritamig was well-tolerated with promising ...

Incorporating mpMRI before TURBT improves bladder cancer-specific survival in patients with suspected MIBC. The BladderPath trial aimed to reduce time to radical treatment by comparing mpMRI before ...

The combination of enfortumab vedotin and pembrolizumab improved event-free survival, overall survival, and pathological complete response in muscle-invasive bladder cancer patients ineligible for ...

A focal point of the discussion was the ARANOTE trial, which examined darolutamide plus ADT versus ADT alone in men with metastatic hormone-sensitive prostate cancer who had not received chemotherapy ...

Srikala Sridhar, MD, MSc, FRCPC, outlines phase 2 data on avelumab in patients with locally advanced or metastatic penile cancer. Panelists discuss the characteristics of an ideal multidisciplinary ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...

The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...